Oslo, Norway, April 29, 2010.

The Annual General Meeting in Photocure ASA took place on April 28, 2010.

Please find attached minutes from the meeting.

For further information, please contact:

President and CEO Kjetil Hestdal
E-mail: kh@photocure.no
Mobile: +47 913 19 535

CFO Christian Fekete
E-mail: cf@photocure.no
Mobile: +47 916 42 938

www.photocure.com

About Photocure

Photocure is a Norwegian pharmaceutical company listed on the Oslo Stock
Exchange (OSE: PHO). The company develops and sells pharmaceuticals and medical
devices for the photodynamic treatment and diagnosis of cancer and selected
dermatology indications.

Photocure's commercial activities includes own marketing and sales in selected
markets as well as out-licensing on a regional or global basis prior to phase
III.

Photocure has one proprietary pharmaceutical product on the market: Hexvix(®),
for the diagnosis of bladder cancer. Hexvix is approved in EU. In addition, the
company has developed a proprietary light source, which is used in combination
with the Visonac(TM) cream. Through worldwide studies, Photocure is continuously
testing its products for new indications, and the aim is to develop a pipeline
of follow-on products based on the Photocure Technology(TM)platform.

For more information about Photocure, visit our website at www.photocure.com.

Photocure(®), the Photocure logo and Hexvix(®) are registered trademarks of
Photocure ASA.

This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)

[HUG#1409868]